Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W15D | ISIN: US00182C1036 | Ticker-Symbol: BSFA
Tradegate
23.04.25
13:11 Uhr
62,50 Euro
+1,00
+1,63 %
1-Jahres-Chart
ANI PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ANI PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
61,0062,0019:07
61,0061,5019:04

Aktuelle News zur ANI PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBuy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue1
ANI PHARMACEUTICALS Aktie jetzt für 0€ handeln
MoTruist raises ANI Pharmaceuticals target to $65, maintains hold6
12.04.Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)3
09.04.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET3
07.04.Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO1
19.03.ANI Pharmaceuticals Launches Nitazoxanide Tablets 500 Mg255WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP), Wednesday announced the launch of Nitazoxanide Tablets, 500 mg that are the generic version of the reference listed drug Alinia.Nikhil...
► Artikel lesen
19.03.ANI Pharmaceuticals launches generic Nitazoxanide Tablets3
19.03.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets122PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI's Nitazoxanide Tablets...
► Artikel lesen
19.03.ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ360WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) Tuesday has completed the buyout of its 3.125 percent perpetual royalty obligation to SWK Funding LLC on global net revenues of ILUVIEN...
► Artikel lesen
18.03.ANI Pharma buys royalties linked to Iluvien and Yutiq2
18.03.ANI PHARMACEUTICALS INC - 8-K, Current Report1
18.03.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN and YUTIQ115BAUDETTE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the buyout of its 3.125% perpetual royalty obligation...
► Artikel lesen
14.03.Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts3
14.03.ANI Pharma Says FDA Approves Expanded ILUVIEN Label To Treat Chronic NIU-PS352WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) announced Friday that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal...
► Artikel lesen
14.03.ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN Label377ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME)ANI plans to begin marketing...
► Artikel lesen
14.03.Jefferies initiates ANI Pharmaceuticals stock with Buy, $80 target4
12.03.ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects2
12.03.JPMorgan sets ANI Pharmaceuticals stock at $85 target2
11.03.ANI PHARMACEUTICALS INC - 8-K, Current Report1
04.03.ANI Pharmaceuticals Receives FDA Approval For Purified Cortrophin Gel Prefilled Syringe340WASHINGTON (dpa-AFX) - ANI Pharmaceuticals Inc. (ANIP) announced that the U.S. Food and Drug Administration approved Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin...
► Artikel lesen
Seite:  Weiter >>
68 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1